Case Info
Leqembi and Kisunla Brain Bleeding Lawsuit
A recent report has stated that certain study participants may not have been adequately warned that they were at an increased risk of brain bleeds or swelling when taking Alzheimer’s medications Leqembi or Kisunla during clinical trials for the drugs.
Clinical studies performed on Eisai’s Alzheimer’s drug Leqembi and Eli Lilly’s similar medication, Kisunla, may have resulted in cases of brain bleeding or brain swelling and at least one death. Patients who entered the clinical studies may not have been adequately informed that their genetic profile placed them at increased risk of such complications.
People or loved ones of those who participated in clinical trials and developed a brain injury after taking Leqembi or Kisunla may be eligible for compensation.
Leqembi and Kisunla Genetic Tests May Have Shown Risks
Research studies typically require that patients receive “informed consent”, before taking a study medication and only after the risks of taking that medication have been disclosed.
Both Eisai and Eli Lilly performed genetic testing on study participants prior to receipt of the medications. However, it has been reported that results of the testing were not disclosed to patients prior to receiving these medications and that these study participants may have had an increased risk of brain injury while taking Leqembi and Kisunla.
Investigative Report Exposes Manufacturers
An investigative report published by the New York Times indicates that patients were not fully informed that their genetic profile placed them at an increased risk to suffer brain injuries. If these study participants were fully informed of the risk, they may have chosen not to participate in these studies.
These patients may have been unfairly placed at significant risk of brain injury due to brain bleeding or swelling. At least one death may have been associated with these complications of the Alzheimer’s medications Leqembi and Kisunla.
Leqembi and Kisunla Alzheimer’s Medications
Eisai’s Leqembi and Eli Lilly’s Kisunla are both used for Alzheimer’s patients. They are intended to work by reducing the presence of beta-amyloid, a protein that forms plaque deposits in the brains of Alzheimer’s patients.
Though both medications have been approved by the FDA, approval of the medications has been controversial around the world. Australian and European Union health authorities have rejected approval of Leqembi and have expressed concerns about similar medications. In some cases, authorities have stated that the drugs do not appear to reduce disease progression, may make the disease worse, or may have serious side effects.
Approval of another Alzheimer’s drug, Aduhelm, was made over objections from members of the FDA’s advisory committee and resulted in subsequent resignation of those members.
People or loved ones of those who participated in a clinical study for the Alzheimer’s drugs Leqembi or Kisunla and developed brain bleeds, brain swelling or who died after taking the medications may be eligible for compensation.